Clinical Trials Logo

Steatosis of Liver clinical trials

View clinical trials related to Steatosis of Liver.

Filter by:

NCT ID: NCT06154096 Not yet recruiting - Steatosis of Liver Clinical Trials

Liver Fat and Glucagon Resistance

Start date: March 2024
Phase:
Study type: Observational

One in four adults worldwide have too much fat stored in the liver which is known as metabolic associated steatotic liver disease (MASLD). This was previously known as non- alcoholic fatty liver disease (NAFLD). This can lead to liver failure and death in severe cases. Unfortunately, there are no specific drugs to treat MASLD. Glucagon is a natural hormone that controls how the body stores and uses fuel. Glucagon acts on liver cells to use protein and fat to make sugar. It decreases the amount of liver fat. The investigators think that patients with MASLD may not respond to the actions of glucagon. This could contribute to the build-up of fat in the liver. In this study the investigators will be investigating the effects of glucagon on protein breakdown and sugar production in patients with and without MASLD. Healthy volunteers and patients with MASLD will attend for one study visit each which will last for 4-5 hours. During this time they will have infusions into a vein of glucagon and other hormones, amino acids (to mimic the fed state) and 'tracers'. From another vein they will have several blood samples during this period. By analysing these blood samples the investigators will be able to measure the effects of glucagon on protein and glucose turnover (metabolism), and whether this differs between healthy volunteers and those with MASLD. If the investigators find that patients with MASLD are resistant to the actions of glucagon, this could help with the development of drugs to treat MASLD.

NCT ID: NCT06021743 Recruiting - Sepsis Clinical Trials

The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis

SepsisFAT
Start date: January 1, 2022
Phase:
Study type: Observational

The impact of the complex liver immunological network on sepsis outcome is largely unknown. Steatotic liver disease (SLD) is the most common chronic liver disease with prevalence of 25% in European countries. The question remains whether patients with SLD are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. Semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with SLD and development of fibrosis, but also might regulate systemic immune responses in sepsis. This study will investigate the association of semaphorins with sepsis outcomes in patients with SLD.

NCT ID: NCT05676177 Enrolling by invitation - Clinical trials for Non-Alcoholic Fatty Liver Disease

CT Liver Fat Fraction Quantification

Start date: January 29, 2023
Phase: N/A
Study type: Interventional

Our aim is to develop an AI based tool to use ultra-low dose CT in two separate energy levels using a single-energy CT machine to quantify liver fat in individuals at risk for having non-alcoholic fatty liver disease (NAFLD), compared to MRI which serves as the standard of reference. Secondary aim of our study is to validate the developed artificial intelligence (AI)-based model on a second group of participants ("external validation").

NCT ID: NCT05651724 Not yet recruiting - Obesity Clinical Trials

Global Research Initiative for Patients Screening on NASH

GRIP on NASH
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

GRIP on NASH will assist primary care physicians and clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe fatty liver disease and to raise awareness on fatty liver disease. The primary objective is to implement a transmural patient care pathway, in order to identify patients with non-alcoholic fatty liver diseases (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) in primary care centres and clinics in 10 European countries.

NCT ID: NCT05479721 Recruiting - NAFLD Clinical Trials

LITMUS Imaging Study

Start date: September 4, 2019
Phase:
Study type: Observational

The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.

NCT ID: NCT05120557 Not yet recruiting - Liver Cirrhosis Clinical Trials

Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH

POCUS-NASH
Start date: September 2022
Phase: N/A
Study type: Interventional

The main objective of the study is to determine the diagnostic performances of an ultraportable diagnostic ultrasound system for the assessment of liver fibrosis severity in patients with NASH, and to compare them to other non-invasive tests.

NCT ID: NCT04442334 Recruiting - Obesity Clinical Trials

The European NAFLD Registry

Start date: May 1, 2015
Phase:
Study type: Observational [Patient Registry]

The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to utilise this information to develop and validate biomarkers that, singly or in combination, enable detection and monitoring of disease progression and/or from NAFL through NASH to fibrosis and cirrhosis.

NCT ID: NCT03858920 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

Start date: May 8, 2018
Phase:
Study type: Observational

This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.

NCT ID: NCT03241121 Completed - Obesity Clinical Trials

Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome

Start date: September 29, 2017
Phase: N/A
Study type: Interventional

SwissChronoFood - Study of eating patterns with a smartphone app and the metabolic effects of time restricted feeding in metabolic syndrome The purpose of this study is to assess eating patterns among teenagers and adults with a new method, going beyond the pen-and-paper food diaries, and to investigate whether time restricted feeding leads to weight loss, improvement in lipid and glucose metabolism in individuals with components of the metabolic syndrome

NCT ID: NCT03203486 Completed - NAFLD Clinical Trials

Response of NAFLD Patients to Mediterranean Diet

Start date: April 2014
Phase: N/A
Study type: Interventional

The effects of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis. Potential associations of single nucleotide polymorphisms to diet composition and patients' profile were also investigated.